Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

Social media platform Discord announced on Feb. 9 that it will begin implementing global age verification starting in March. The company said in a news release that the phased rollout will require ...

Discord has announced plans to enforce a new "teen-appropriate" experience by default next month, requiring age verification to access restricted content or change content settings. In a blog post ...

Discord is facing backlash after announcing that all users will soon be required to verify ages to access adult content by sharing video selfies or uploading government IDs. According to Discord, it’s ...

Discord will soon require users globally to verify their age with a face scan or by uploading a form of ID if they want to access adult content. The online chat service, which allows people to create ...

A Python-based malware family known as VVS stealer has been observed using advanced obfuscation and stealth techniques to target Discord users and extract sensitive ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

The "Unable to Accept Invite" error in Discord might be due to an expired invite link or the user reaching the server limit. To fix this, ensure the invite link is ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...